Aurobindo will shell out $250 million to acquire drugmaker Lannett, shoring up the Indian drugmaker’s footprint in the U.S.

Aurobindo Pharma USA will acquire Lannett from Lannett Seller Holdco for $250 million on a cash-free, debt-free basis.

Hyderabad: Amid rising fears of US President Donald Trump imposing tariffs on Indian pharma imports, Aurobindo Pharma is ...

Aurobindo Pharma to acquire US-based Lannett for $250M, gaining a strategic local manufacturing base to offset tariffs and ...

Hyderabad: In a major strategic move, Aurobindo Pharma Limited has announced that its wholly owned subsidiary, Aurobindo ...

The deal is being carried out on a cash-free, debt-free basis, factoring in standardised working capital levels.

The transaction is valued at an enterprise value of $250 million (₹21,850 crore) on a cash-free, debt-free basis, including ...

Aurobindo Pharma USA acquires Lannett Company LLC for $250 million, expanding U.S. manufacturing capabilities and product ...

HDFC Mutual Fund has launched NFO under its “thematic category”, named as HDFC Innovation Fund. The open ended fund aims to generate long-term capital appreciation / income by investing in companies ...

Lannett is working to complete the financial restructuring transaction by June 18.

TREVOSE, Pa., Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that its Board of Directors approved a 1-for-4 reverse stock split of its issued and outstanding ...

As the nationwide Adderall shortage rolls on, two more companies are joining the long list of suppliers struggling to meet demand. Lannett Co. and Par Pharmaceuticals joined Teva, Amneal ...